Izamby (Denosumab)

Denosumab is a monoclonal antibody that binds to RANK ligand (RANKL), blocking its activation of the RANK receptor on osteoclast precursors and mature osteoclasts. This inhibition stops osteoclast formation and activity, leading to reduced bone resorption and increased bone density.

The dose of Izamby is determined by the prescribing healthcare professional based on the specific indication, patient weight, renal function and other clinical factors. The product is supplied as a pre‑filled solution for subcutaneous injection, and the prescriber sets the exact dosing schedule.

Safety of denosumab in pregnancy and lactation has not been established. It is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Women of childbearing potential should use effective contraception during treatment.

To order Izamby, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details (if applicable) and necessary import documentation.

Both denosumab (Izamby) and bisphosphonates are anti‑resorptive agents, but denosumab is a monoclonal antibody administered subcutaneously every six months, whereas bisphosphonates are oral or intravenous agents taken more frequently. Denosumab offers rapid and reversible inhibition of bone resorption, while bisphosphonates bind to bone mineral and have a longer skeletal half‑life.

Izamby should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and ensure proper cold‑chain conditions during transport.

Izamby is supplied as a sterile solution for injection and is given subcutaneously by a healthcare professional. The injection is typically administered in the upper arm, thigh or abdomen, following aseptic technique and according to the dosing schedule prescribed for the specific indication.

Serious risks include severe hypocalcemia, osteonecrosis of the jaw (ONJ), atypical femur fractures, and severe hypersensitivity reactions such as anaphylaxis. Patients should be monitored for signs of low calcium, oral pain, or unusual thigh pain, and dental evaluation is recommended before starting therapy.

Izamby is contraindicated in patients with known hypersensitivity to denosumab or any component of the formulation. It should be used with caution in individuals with severe renal impairment, untreated hypocalcemia, or those planning invasive dental procedures, and it is generally avoided during pregnancy unless absolutely necessary.